

**South Central Priorities Committees**  
(Milton Keynes, Oxfordshire, Berkshire East, Berkshire West and Buckinghamshire PCTs)

**Policy Recommendation 62: Dose escalation therapy with infliximab and adalimumab in people aged 6–17 years with severe active Crohn’s disease**

**This policy recommendation should be considered together with:**

- **Policy recommendation 61: Dose escalation therapy with infliximab and adalimumab in adult patients (18 or older) with severe active Crohn’s disease**
- **Policy recommendation 60: Dose escalation therapy with infliximab and adalimumab in people with active fistulising Crohn’s disease**

**Date of issue: December 2011**

The South Central Priorities Committee (Milton Keynes, Oxfordshire, Buckinghamshire, Berkshire East and Berkshire West) has considered the evidence for dose escalation therapy with infliximab and adalimumab in patients with severe Crohn’s disease. NHS funding of dose escalation therapy with infliximab or adalimumab for the treatment of people aged 6–17 years with severe active Crohn’s disease who fail to maintain their initial response to the drug should be considered **LOW PRIORITY** due to lack of evidence of cost-effectiveness.

The recommendations made in the **NICE technology appraisal guidance 187** ‘*Infliximab (review) and adalimumab for the treatment of Crohn’s disease*’ include;

*Infliximab, within its licensed indication, is recommended for the treatment of people aged 6–17 years with severe active Crohn’s disease whose disease has not responded to conventional therapy (including corticosteroids, immunomodulators and primary nutrition therapy), or who are intolerant of or have contraindications to conventional therapy. The need to continue treatment should be reviewed at least every 12 months.*

**NOTES:**

1. *Exceptional circumstances may be considered where there is evidence of significant health impairment and there is also evidence of the intervention improving health status.*
2. *This policy will be reviewed in the light of new evidence or guidance from NICE.*
3. *South Central policy recommendations can be viewed at <http://www.sph.nhs.uk/priorities/policy-statements>*